Core Viewpoint - The company Changshan Pharmaceutical has received approval from the National Medical Products Administration for a clinical trial of its drug, Aibennatide injection, aimed at weight loss indications [1] Group 1: Company Developments - Changshan Pharmaceutical and its subsidiary, Changshan Kaijie Jian Biological Pharmaceutical Research (Hebei) Co., Ltd., have jointly submitted a clinical trial application for Aibennatide injection, which has now been approved [1] - Aibennatide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) that is developed using DACTM technology, chemically modifying Exenatide and combining it with recombinant human serum albumin to form a new stable compound [1] Group 2: Drug Mechanism and Benefits - GLP-1RA works by activating the GLP-1 receptor in a glucose concentration-dependent manner, stimulating insulin secretion and suppressing glucagon secretion [1] - The drug also increases glucose uptake in muscle and fat tissues, inhibits hepatic glucose production, suppresses gastric emptying, and reduces appetite, thereby exerting its hypoglycemic effects [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-29 河北常山生化药业股份有限公司 关于获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）及控股子公司常山凯 捷健生物药物研发（河北）有限公司（以下简称"常山凯捷健"）于近日收到国 家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》，由双方联 合申报的艾本那肽注射液用于减重适应症的临床试验申请获得批准，现将有关详 情公告如下： 一、药品的基本情况 药品名称：艾本那肽注射液 剂型：注射液 注册分类：化学药品 1 类 申请事项：临床试验 受理号：CXHL2500378 申请人：河北常山生化药业股份有限公司、常山凯捷健生物药物研发（河北） 有限公司 审批结论：经审查，2025 年 4 月 10 日受理的艾本那肽注射液临床试验申请符 合药品注册的有关要求，同意本品在成人肥胖或超重患者中开展临床试验。 二、药品的其他相关情况 艾本那肽是一种长效胰高血糖素样肽-1 受体激动剂（GLP-1RA），是利用药物 亲和力偶合 ...

Core Viewpoint - Changshan Pharmaceutical has received approval for clinical trials of Aibennapeptide injection for weight loss indications, marking a significant step in its drug development process [1] Company Summary - Changshan Pharmaceutical (300255.SZ) and its subsidiary Changshan Kaijiejian have obtained the clinical trial approval notice from the National Medical Products Administration for Aibennapeptide injection [1] - Aibennapeptide is a long-acting glucagon-like peptide-1 receptor agonist that stimulates insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, while also promoting glucose uptake in muscle and fat tissues and suppressing hepatic glucose production [1] - The approval for clinical trials does not have a significant impact on the company's recent performance, as further clinical trials and regulatory reviews are required before the drug can be marketed [1] Industry Summary - The drug development process is characterized by high investment, long cycles, and significant risks, with various uncertainties affecting clinical trial outcomes and market competition [1] - The approval of clinical trials is just the beginning, as the drug must undergo further testing and regulatory scrutiny before it can be launched in the market [1]

Market Overview - On June 19, A-shares opened lower and continued to decline, with the Shanghai Composite Index falling by 0.79% to 3362 points, the Shenzhen Component Index down by 1.21%, and the ChiNext Index down by 1.36%, with over 4600 stocks declining across the market [1] - Market focus shifted towards the oil, natural gas, and digital reading sectors [1] High-Performing Stocks - In the oil and gas sector, Zhuan Oil Co. and Shandong Molong achieved five consecutive trading limits, while military stock Beifang Changlong saw a 20% increase over three days [3] - Notable stocks with significant gains include: - Shandong Quanlong: +10.00%, five consecutive limits [4] - Zhuan Oil Co.: +9.96%, five consecutive limits [4] - Beifang Changlong: +20.01%, three limits in five days [4] - Innovation Medical: +10.04%, two limits in three days [4] Trading Activity - The top three net purchases on the Dragon and Tiger list were: - Innovation Medical: net purchase of 207 million [5] - Electric Science Cybersecurity: net purchase of 153 million [5] - Anni Co.: net purchase of 135 million [5] - The top three net sales were: - Limin Co.: net sale of 230 million [7] - Xiexin Energy: net sale of 218 million [7] - Changshan Pharmaceutical: net sale of 178 million [7] Sector Highlights - Innovation Medical focuses on brain-machine interfaces and AI medical models, achieving a trading limit with a turnover of 1.745 billion and a turnover rate of 31.78% [10] - Baida Qiancheng, involved in short drama games and major contract signings, also reached a trading limit with a turnover of 1.077 billion [14] - Electric Science Cybersecurity, which focuses on digital currency and satellite navigation, achieved a trading limit with a turnover of 694 million [18] Institutional Activity - Institutions showed significant interest in several stocks, with net purchases in: - Electric Science Cybersecurity: 35 million [22] - Innovation Medical: 26 million [22] - Shandong Molong: 20 million [22] - Conversely, institutions sold off stocks like Limin Co. and Xiexin Energy, with net sales of 64 million and 71 million respectively [19][22] Conclusion - The market experienced a downward trend with specific sectors like oil and gas showing resilience through notable stock performances. Institutional trading patterns indicate selective interest in high-growth potential stocks, particularly in the technology and healthcare sectors.

常山药业今日跌停，全天换手率7.18%，成交额33.95亿元，振幅23.72%。龙虎榜数据显示，机构净卖出 9705.97万元，深股通净卖出7457.39万元，营业部席位合计净卖出682.95万元。 深交所公开信息显示，当日该股因日收盘价跌幅达-20.00%上榜，机构专用席位净卖出9705.97万元，深 股通净卖出7457.39万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交6.99亿元，其中，买入成交额为2.60亿 元，卖出成交额为4.39亿元，合计净卖出1.78亿元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即卖二、卖三、卖五，合计买入金额 3224.48万元，卖出金额1.29亿元，合计净卖出9705.97万元，深股通为第一大买入营业部及第一大卖出 营业部，买入金额为9596.40万元，卖出金额为1.71亿元，合计净卖出7457.39万元。 近半年该股累计上榜龙虎榜5次，上榜次日股价平均涨3.12%，上榜后5日平均涨6.28%。 资金流向方面，今日该股主力资金净流出6.17亿元，其中，特大单净流出5.65亿元，大单资金净流出 5115.93万元。近5日主力资金净流出7.73 ...

暗盘资金正涌入这些股票，点击速看>>> 常山药业（300255）今日跌停，成交额33.95亿元，换手率7.18%，盘后龙虎榜数据显示，深股通专用席 位买入9596.40万元并卖出1.71亿元，三机构专用席位净卖出9705.97万元。 ...

Market Overview - The three major indices experienced a decline, with the ChiNext Index dropping by 1.1% and over 4600 stocks in the market showing negative performance [1][3] - The Shanghai Composite Index fell by 0.86%, the Shenzhen Component Index decreased by 1.01%, and the North China 50 Index also saw a nearly 1% drop, with trading volume exceeding 800 billion, an increase of over 40 billion compared to the previous day [3] Economic Factors - Recent macroeconomic data has shown signs of pressure, leading to hesitance in market recovery expectations [3] - Popular sectors such as AI and weight-loss drugs are experiencing corrections, prompting funds to shift towards defensive sectors [3] - External market instability has also contributed to negative sentiment in the domestic market [3] Sector Performance - Solid-state batteries, PCB, and oil sectors saw gains, with stocks like Nord and Xiangtan Electric achieving limit-up [3] - The solid-state battery sector is gaining attention due to recent technological breakthroughs and a reasonable valuation after previous adjustments in the new energy sector [3] - The oil sector's rise may be linked to geopolitical tensions in the Middle East, particularly the potential for U.S. actions against Iran, leading to short-term oil price volatility [3] Declining Sectors - The nuclear fusion, military, and weight-loss drug sectors faced significant declines, with Changshan Pharmaceutical hitting the limit down and Hanyu Pharmaceutical dropping over 10% [4] - The military sector's adjustment is attributed to a lack of new catalysts, leading to fund withdrawals [4] - The nuclear power sector saw stocks like Hezhan Intelligent and China Nuclear Technology hitting the limit down, possibly due to negative news from specific companies [4] Investment Strategy - In a broad market decline, it is essential to maintain a calm mindset and focus on identifying quality stocks [4] - Long-term investors should prioritize company fundamentals and industry prospects over short-term price fluctuations [4] - The solid-state battery sector is highlighted as a promising long-term investment, while caution is advised in the weight-loss drug sector due to speculative trading [4]

智通财经6月19日电，早盘创新药概念延续调整，常山药业触及20CM跌停，翰宇药业跌超10%，通化金 马、广生堂、赛升药业、舒泰神等跟跌。 创新药概念延续调整 常山药业触及跌停 ...

常山药业跳水，一度触及跌停，现跌幅收窄至17%，成交额超17亿元。 ...

暗盘资金正涌入这些股票，点击速看>>> 化学制药板块短线走低，常山药业（300255）跌超12%，永安药业（002365）、翰宇药业（300199）、 通化金马（000766）、广生堂（300436）等跟跌。 ...